Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted Depreciation & Amortization (CF) of $152000.0 for Q2 2026, down 5.59% on a QoQ basis from $161000.0 in Q1 2026, and down 36.67% year-over-year from $240000.0 in Q2 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $152000.0 in Q2 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 36.67% year-over-year to $152000.0 in Q2 2026; TTM through Jun 2026 was $722000.0, a 28.94% decrease from a year earlier, with the FY2025 full-year figure at $900000.0, down 12.45% from the prior year.
- Depreciation & Amortization (CF) was $152000.0 for Q2 2026 at Rani Therapeutics Holdings, down from $161000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $266000.0 in Q4 2024, with the low at $111000.0 in Q1 2022.
- Average Depreciation & Amortization (CF) over 5 years is $200611.1, with a median of $203500.0 recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: Depreciation & Amortization (CF) soared 69.37% in 2023, then plunged 36.67% in 2026.
- Over 5 years, Depreciation & Amortization (CF) stood at $174000.0 in 2022, then soared by 30.46% to $227000.0 in 2023, then grew by 17.18% to $266000.0 in 2024, then sank by 30.08% to $186000.0 in 2025, then slipped by 18.28% to $152000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $152000.0 (Q2 2026), $161000.0 (Q1 2026), and $186000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 600,000.00 |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | 152,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 152,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 259,000.00 |
| Jun 30, 2024 | 255,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 227,000.00 |
| Sep 30, 2023 | 218,000.00 |
| Jun 30, 2023 | 189,000.00 |
| Mar 31, 2023 | 188,000.00 |
| Dec 31, 2022 | 174,000.00 |
| Sep 30, 2022 | 141,000.00 |
| Jun 30, 2022 | 122,000.00 |
| Mar 31, 2022 | 111,000.00 |
| Dec 31, 2021 | 113,000.00 |
| Sep 30, 2021 | 120,000.00 |